Automate Your Wheel Strategy on IBO
With Tiblio's Option Bot, you can configure your own wheel strategy including IBO - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol IBO
- Rev/Share 0.0006
- Book/Share -0.6056
- PB -0.7004
- Debt/Equity -2.1615
- CurrentRatio 0.0639
- ROIC -1.6199
- MktCap 7183562.0
- FreeCF/Share -0.2821
- PFCF -2.0895
- PE -0.1883
- Debt/Assets 1.1727
- DivYield 0
- ROE -5.2869
- Rating C
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 1
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| No ratings available. | |||||||
News
Impact Biomedical Inc (IBO) Announces 3F™ US Patent Issue
Published: August 18, 2025 by: GlobeNewsWire
Sentiment: Neutral
HOUSTON, Aug. 18, 2025 (GLOBE NEWSWIRE) -- Impact Biomedical Inc. (IBO) is pleased to announce that the US Patent and Trademark Office has issued U.S. patent No. 12,357,584 B2 entitled “Composition and Method of Controlling Infectious Diseases with Functional Fragrances,” developed within IBO's 3F™ technology platform.
Read More
IBO Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Impact BioMedical Inc. Is Fair to Shareholders
Published: June 30, 2025 by: Business Wire
Sentiment: Neutral
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the merger of Impact BioMedical Inc. (NYSE American: IBO) and Dr Ashleys Limited is fair to Impact shareholders. Halper Sadeh encourages Impact shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or [email protected] or [email protected]. The investigation concerns whether Impact and its board violated.
Read More
Dr Ashleys Limited and Impact BioMedical Inc. Announce Strategic Merger
Published: June 23, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, June 23, 2025 (GLOBE NEWSWIRE) -- Dr Ashleys Limited, a Hong Kong based global pharmaceutical company (“Dr Ashleys”), and Impact BioMedical Inc. (“Impact BioMedical”) (NYSE American: IBO), a Texas based biopharmaceuticals developer listed on the New York Stock Exchange American (“Impact BioMedical”, together with Dr Ashleys, the “Parties”), are pleased to announce the execution of a merger and share exchange agreement (the “Merger Agreement”) on June 21, 2025 to enter into a strategic merger transaction (the “Transaction”). Upon closing of the Transaction, Dr. Ashleys will acquire Impact BioMedical through a reverse merger that will result in a newly …
Read More
Impact Biomedical Inc. Announcement Stock Activity/Pricing
Published: March 21, 2025 by: GlobeNewsWire
Sentiment: Neutral
HOUSTON, March 21, 2025 (GLOBE NEWSWIRE) -- Impact BioMedical Inc. (NYSE American: IBO), a pioneering biotechnology company dedicated to discovering, developing, and patenting innovative healthcare solutions, today announced that there has been no material development in its business affairs not previously disclosed or, to its knowledge, any other reason to account for the unusual market action regarding its share price.
Read More
About Impact BioMedical Inc. (IBO)
- IPO Date
- Website https://www.impactbiomedinc.com
- Industry Biotechnology
- CEO Frank D. Heuszel
- Employees 2